- Conditions
- Hypertension
- Interventions
- High Intensity Interval Training (HIIT) Exercise
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 55 Years to 75 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1537–1560
of 1,622
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
- Interventions
- Specimen sample
- Diagnostic Test
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Age - Related Macular Degeneration (AMD)
- Interventions
- Intravitreal Aflibercept Injection (IAI)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 46 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Brolucizumab, Aflibercept
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 517 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 74
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 66 more
- Conditions
- Retinal Degenerations
- Interventions
- 2% dorzolamide
- Drug
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Retinal Disease
- Interventions
- P200TxE
- Device
- Lead sponsor
- Optos, PLC
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Geographic Atrophy
- Interventions
- Lampalizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Not listed
- Enrollment
- 994 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 122
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 103 more
- Conditions
- Kidney Failure, Chronic, Eye Diseases, Diabetic Retinopathy
- Interventions
- RetinaVue 100 camera
- Device
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Maculopathy, Age-Related
- Interventions
- Anecortave Acetate 15 mg, Triamcinolone Acetate 4 mg, Photodynamic Therapy with Verteporfin, Thermal Laser
- Drug · Procedure
- Lead sponsor
- Manhattan Eye, Ear & Throat Hospital
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Macular Edema
- Interventions
- AIV007
- Drug
- Lead sponsor
- AiViva BioPharma, Inc.
- Industry
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Santa Ana, California • Eugene, Oregon + 3 more
- Conditions
- Telangiectasia
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Retinitis Pigmentosa Syndromic, Congenital Deafness, Usher Syndrome, Retinitis Pigmentosa and Deafness, Retinitis Pigmentosa
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • New York, New York
- Conditions
- Age-Related Macular Degeneration, Diabetic Retinopathy, Central Serous Chorioretinopathy, Glaucoma, Glaucoma, Suspect, Eye Diseases
- Interventions
- OCT Imaging Using Device N, OCT Imaging Using Device C
- Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetic Macular Edema, Epiretinal Membrane
- Interventions
- Ozurdex
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Primary Open Angle Glaucoma
- Interventions
- AMDX-2011P
- Drug
- Lead sponsor
- Amydis Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Glendale, California • Newport Beach, California
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)
- Drug
- Lead sponsor
- Light Sciences LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Retinitis Pigmentosa
- Interventions
- New visual processing unit (VPU) with asymmetric waveforms, New VPU with bipolar stimulation
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 25 Years to 89 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Sodium Nitroprusside, 5% Dextrose solution
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetic Retinopathy
- Interventions
- I-SITE Intervention, Usual Care Teleophthalmology
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12,840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Gyrate Atrophy, Gyrata of Choroid and Retina; Atrophy, Ornithine-δ-aminotransferase, OAT, Chorioretinal Degeneration
- Interventions
- Not listed
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 4
- States / cities
- San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Diabetic Retinopathy (DR)
- Interventions
- Fundus Image Grading
- Diagnostic Test
- Lead sponsor
- Artelus AI
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Oxford, North Carolina • Raleigh, North Carolina
- Conditions
- Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
- Interventions
- BS01, Sham procedure control
- Biological · Other
- Lead sponsor
- Bionic Sight LLC
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Edison, New Jersey
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Valganciclovir, Ganciclovir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 14 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2002
- U.S. locations
- 15
- States / cities
- Irvine, California • La Jolla, California • San Diego, California + 8 more
- Conditions
- Stargardt's Disease
- Interventions
- SAR422459
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 4
- States / cities
- Miami, Florida • Iowa City, Iowa • Portland, Oregon + 1 more